Continued Access to Darunavir/Ritonavir (DRV/Rtv) in HIV-1-Infected Adults (Roll Over Patients From C211, C214 & C229)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2016
At a glance
- Drugs Darunavir (Primary) ; Ritonavir
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Janssen R&D Ireland
- 20 May 2016 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 20 May 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2017.
- 20 Nov 2015 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov record.